English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/220030
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity

AuthorsBueno, Clara; Velasco-Hernández, Talia CSIC ORCID; Gutiérrez-Agüera, Francisco; Zanetti, Samanta Romina; Baroni, Matteo L.; Sánchez-Martínez, Diego; Molina, Oscar; Closa, Adria; Agraz-Doblas, Antonio; Marín, Pedro; Eyras, Eduardo; Varela, Ignacio CSIC ORCID; Menendez, Pablo
KeywordsAcute lymphocytic leukaemia
Issue Date2019
PublisherSpringer Nature
CitationLeukemia 33: 2090-2125 (2019)
AbstractChimeric antigen receptors (CARs) have undoubtedly revolutionized immunotherapy, especially in the B-cell acute lymphoblastic leukemia (ALL) arena where over 80% of complete remissions are observed in refractory/relapsed (R/R) B-cell ALL patients treated with CD19-directed CAR T-cells (CARTs) [1]. However, despite holding an unprecedented promise, several issues still have to be resolved before CARTs can be expanded to novel targets and/or malignancies or even provided as first-line treatment in Bcell ALL [2]. For instance, toxicities such as cytokine release syndrome and immune escape mechanisms including loss of the antigen under CART-mediated pressure remain major concerns, urging further research on the mechanisms underlying CARTs cytotoxicity.
Description© The Author(s) 2019.
Publisher version (URL)https://doi.org/10.1038/s41375-019-0418-8
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
CD133-directed_Bueno_Art2019.pdfCD133-directed_Bueno_Art2019800,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.